Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Top Stocks Fund Managers Are Loading Up On in 2026.

Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9

On March 30, 2026, Merck & Co., Inc. (NYSE:MRK) announced positive Phase 3 CORALreef AddOn trial results for enlicitide decanoate, an investigational once-daily oral PCSK9 inhibitor. The study was presented at the American College of Cardiology’s 2026 Scientific Session, where Merck & Co., Inc. (NYSE:MRK) demonstrated that enlicitide reduced LDL-C by 64.6% from baseline when added to statins. The therapy performed higher than bempedoic acid and ezetimibe, with 78.2% of patients achieving a prespecified LDL-C goal of less than 55 mg/dL. Enlicitide also showed statistically significant reductions in apolipoprotein B and non-high-density lipoprotein cholesterol. With the safety profile remaining consistent with previous trials, with no serious adverse events, the company is looking forward to launching what could be the first approved oral PCSK9 inhibitor.

In a prior development, on March 25, 2026, Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement with Terns Pharmaceuticals, Inc., a clinical-stage oncology company, to acquire the company for $6.7 billion. With this acquisition, the company aims to expand its hematology portfolio and further diversify and strengthen its position in oncology.

Founded in 1891, Merck & Co., Inc. (NYSE:MRK) is a global biopharmaceutical leader that provides innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. The company is based in New Jersey and focuses on multiple areas, including oncology, cardiovascular, infectious diseases, and respiration.

While we acknowledge the risk and potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 11 Best Stocks You’ll Wish You Bought Sooner and 15 Set-It-and-Forget-It Stocks to Buy in 2026

Disclosure: None.  Follow Insider Monkey on Google News.